

# The Bioconductor Project for Reproducible Analysis of High Throughput Genomic Data

Martin Morgan ([mtmorgan@fhcrc.org](mailto:mtmorgan@fhcrc.org))  
Fred Hutchinson Cancer Research Center

19-21 January, 2011

# Analysis and Comprehension of High Throughput Genomic Data

## Hallmarks of effective computational software

1. Extensive: data, annotation
2. Statistical: volume, technology, experimental design
3. Reproducible: long-term, multi-participant science
4. Leading edge: novel, technology-driven
5. Accessible: affordable, transparent, usable

# 1. Extensive Data and Annotation

## Data

- ▶ Expression, tiling, methylation, custom arrays.
- ▶ Sequence analysis, e.g., ChIP-, RNA-seq
- ▶ Other high-throughput assays, e.g., flow cytometry, mass spec., imaging
- ▶ Public repositories, e.g., GEO, ArrayExpress
- ▶ Validating experimental data

## Annotation, e.g.,

- ▶ Well-curated: NCBI, Biomart, UCSC, MsigDB, GO, KEGG
- ▶ Loosely curated: emerging, specialized, & lab-based
- ▶ Consortium: HapMap, 1000 genomes, TCGA

# Bioconductor

**Goal** Help biologists understand their data

**Focus**

- ▶ Expression and other microarray; flow cytometry
- ▶ High-throughput sequencing

**Themes**

- ▶ Contributions from 'core' members and (primarily academic) user community
- ▶ Based on the *R* programming language – statistics, visualization, interoperability
- ▶ Reproducible – scripts, *vignettes*, packages
- ▶ Open source / open development

**Success** > 400 packages; publications; very active mailing list; annual conferences; courses; ...

## Bioconductor: Sample Work Flow

```
> ##  
> ## Pre-processing  
> library(affy)  
> eset <- just.rma()  
> ##  
> ## Quality assessment  
> library(arrayQualityMetrics)  
> arrayQualityMetrics(eset)  
> ##  
> ## Differential expression  
> library(limma)  
> status <-  
+   c("Trt", "Trt", "Trt", "Ctrl", "Ctrl", "Ctrl")  
> design <- model.matrix( ~status )  
> fit <- eBayes(lmFit(eset, design))  
> topTable(fit, coef=2)
```

## 2. Statistical

### Technology


- ▶ Acknowledging artifacts and biases
- ▶ Accomodate using statistical models, e.g., RMA

### Volume

- ▶ Data reduction essential
- ▶ Inference

### Experimental design

- ▶ Exploratory analysis
- ▶ Hypothesis-driven; designed experiments
- ▶ Cost-effective, but not too clever



Expression array. Pseudocolors represent hybridisation intensities of RNA to features. Source: [url](#)

# Statistical

## Technology


- ▶ Acknowledging artifacts and biases
- ▶ Accomodate using statistical models, e.g., RMA

## Volume

- ▶ Data reduction essential
- ▶ Inference

## Experimental design

- ▶ Exploratory analysis
- ▶ Hypothesis-driven; designed experiments
- ▶ Cost-effective, but not too clever



Measured intensity increases with GC content; Chronic Lymphocytic Leukemia (CLL) dataset.

# Statistical

## Technology


- ▶ Acknowledging artifacts and biases
- ▶ Accomodate using statistical models, e.g., RMA

## Volume

- ▶ Data reduction essential
- ▶ Inference

## Experimental design

- ▶ Exploratory analysis
- ▶ Hypothesis-driven; designed experiments
- ▶ Cost-effective, but not too clever



Heatmap summarizing distance between CLL arrays



# Statistical

## Technology


- ▶ Acknowledging artifacts and biases
- ▶ Accomodate using statistical models, e.g., RMA

## Volume

- ▶ Data reduction essential
- ▶ Inference

## Experimental design

- ▶ Exploratory analysis
- ▶ Hypothesis-driven; designed experiments
- ▶ Cost-effective, but not too clever



Normalized unscaled standard error (NUSE) suggests array CLL1 is an outlier.

# Statistical

## Technology


- ▶ Acknowledging artifacts and biases
- ▶ Accomodate using statistical models, e.g., RMA

## Volume

- ▶ Data reduction essential
- ▶ Inference

## Experimental design

- ▶ Exploratory analysis
- ▶ Hypothesis-driven; designed experiments
- ▶ Cost-effective, but not too clever



‘Progressive’ vs. ‘stable’ status.  
log  $P$  vs. log-fold change, CLL  
data set. Probe sets with extreme  
differentiation highlighted.

### 3. Reproducible Research

#### Long-term

- ▶ Returning to analysis after days, weeks, months of other activity

#### Multi-participant: communicating with...

- ▶ Other statisticians / bioinformaticians
- ▶ Biologists and others without specialized statistical knowledge

#### Science: reproducibility facilitating...

- ▶ Third-party verification
- ▶ Critical assessment
- ▶ Challenging, even in high-profile journals requiring archived raw data (Ioannidis *et al.*, 2009, Nat Genet 41: 149-155).

# Reproducible Research: Case Study

## Original research

- ▶ Potti *et al.*, 2006; Hsu *et al.*, 2007
- ▶ NCI60 cell line drug sensitivity signature
- ▶ Clinical trial allocation

## Reproducibility

- ▶ Baggerly & Coombes, 2009
- ▶ Off-by-one cisplatin gene signature
- ▶ Four 'interesting' genes not supported by analysis (two not on array)

## References

- ▶ Potti *et al.* 2006 Nat Med 12: 1294-1300; (retracted)
- ▶ Hsu *et al.* 2007 J Clin Oncol 25: 4350-4357. (retracted)
- ▶ Baggerly & Coombes 2009 Ann Appl Stat 3: 1309-1334


# Reproducible Research: Case Study

## Original research

- ▶ Potti *et al.*, 2006; Hsu *et al.*, 2007
- ▶ **NCI60 cell line drug sensitivity signature**
- ▶ Clinical trial allocation

## Reproducibility

- ▶ Baggerly & Coombes, 2009
- ▶ Off-by-one cisplatin gene signature
- ▶ Four 'interesting' genes not supported by analysis (two not on array)



Hsu *et al.*, cisplatin, fig. 1a


# Reproducible Research: Case Study

## Original research

- ▶ Potti *et al.*, 2006; Hsu *et al.*, 2007
- ▶ NCI60 cell line drug sensitivity signature
- ▶ Clinical trial allocation

## Reproducibility

- ▶ Baggerly & Coombes, 2009
- ▶ **Off-by-one cisplatin gene signature**
- ▶ Four 'interesting' genes not supported by analysis (two not on array)



Baggerly & Coombes, fig. 2a


# Reproducible Research: Case Study

## Original research

- ▶ Potti *et al.*, 2006; Hsu *et al.*, 2007
- ▶ NCI60 cell line drug sensitivity signature
- ▶ Clinical trial allocation

## Reproducibility

- ▶ Baggerly & Coombes, 2009
- ▶ **Off-by-one cisplatin gene signature**
- ▶ Four 'interesting' genes not supported by analysis (two not on array)



Baggerly & Coombes, fig. 2b


# Reproducible Research: Case Study

## Original research

- ▶ Potti *et al.*, 2006; Hsu *et al.*, 2007
- ▶ NCI60 cell line drug sensitivity signature
- ▶ Clinical trial allocation

## Reproducibility

- ▶ Baggerly & Coombes, 2009
- ▶ **Off-by-one cisplatin gene signature**
- ▶ Four 'interesting' genes not supported by analysis (two not on array)



Baggerly & Coombes, fig. 2d



# Reproducible Research: Case Study

## Original research

- ▶ Potti *et al.*, 2006; Hsu *et al.*, 2007
- ▶ NCI60 cell line drug sensitivity signature
- ▶ Clinical trial allocation

## Reproducibility

- ▶ Baggerly & Coombes, 2009
- ▶ Off-by-one cisplatin gene signature
- ▶ Four 'interesting' genes not supported by analysis (two not on array)

*... results incorporate several simple errors that may be putting patients at risk. One theme that emerges is that the most common errors are simple (e.g., row or column offsets); conversely, it is our experience that the most simple errors are common – Baggerly & Coombes, 2009*

# Reproducible Results: *Bioconductor*

- Script-based Data transformations *necessarily* documented
- 'Literate programming' Text documents embed scripts, scripts *evaluated* when text document processed
- Versioned software and repositories Record which package versions used, and retrieve from *Bioconductor* archives
- Integrated data containers Sample descriptions and expression data in a single object. Subsetting expression data automatically subsets sample descriptions

## 4. Leading Edge

Technological innovations

- ▶ E.g., SNP, miRNA arrays
- ▶ E.g., lab sequencing platforms; novel protocols


Fast-changing

- ▶ Commercial software products not yet developed, or already out-of-date
- ▶ Research questions require novel solutions

# Leading Edge: Illustration

## Sequencing technologies

- ▶ Historically (e.g., 2 years ago): short reads, low 'tail' quality, tail base call bias, data volume
- ▶ Current: count models, read bias, designed experiments, variant representations, annotation




Bentley et al., 2008, Nature 456:  
53-9

# Leading Edge: Illustration

## Sequencing technologies


- ▶ **Historically** (e.g., 2 years ago): short reads, low 'tail' quality, tail base call bias, data volume
- ▶ Current: count models, read bias, designed experiments, variant representations, annotation



# Leading Edge: Illustration

## Sequencing technologies


- ▶ **Historically** (e.g., 2 years ago): short reads, low 'tail' quality, tail base call bias, data volume
- ▶ **Current**: count models, read bias, designed experiments, variant representations, annotation



# Leading Edge: Illustration

## Sequencing technologies

- ▶ Historically (e.g., 2 years ago): short reads, low 'tail' quality, tail base call bias, data volume
- ▶ **Current:** count models, read bias, designed experiments, variant representations, annotation



Poisson (purple) and negative binomial (orange) fit to RNA-seq data. Anders & Huber, 2010, Genome Biol, 11:R106

## 5. Accessible

### Affordable

- ▶ Purchase / licensing; time

### Transparent

- ▶ Algorithms, e.g., RMA
- ▶ Code reuse

### Challenges and solutions

- ▶ Research questions requiring 'one-off' solutions
- ▶ Software bugs

### Usable

- ▶ Documentation
- ▶ Training, such as today!



# Accessible

## Affordable

- ▶ Purchase / licensing; time

## Transparent

- ▶ Algorithms, e.g., RMA
- ▶ Code reuse

## Challenges and solutions

- ▶ Research questions requiring 'one-off' solutions
- ▶ Software bugs

## Usable

- ▶ Documentation
- ▶ Training, such as today!

## Documentation

- ▶ Help pages
- ▶ Vignettes
- ▶ Archived course and conference material
- ▶ Mailing list

## BioC2011

- ▶ Annual conference – user and scientific presentations, workshops, poster session
- ▶ Seattle July 27-29

# Acknowledgments

- ▶ Vince Carey (Brigham & Womens, Harvard), Wolfgang Huber (EBI), Rafael Irizzary (JHU), Robert Gentleman (Genentec)
- ▶ Hervé Pagès, Marc Carlson, Nishant Gopalakrishnan, Chao-Jen Wong, Dan Tenenbaum, Valerie Obenchain
- ▶ Patrick Aboyoun, Seth Falcon, Michael Lawrence, Deepayan Sarkar, Florian Hahne
- ▶ Sean Davis, James MacDonald